Showing 121-140 of 8668 for: Cochrane Systematic Reviews Back
- Acyclovir for treating varicella in otherwise healthy children and adolescents
Cochrane Systematic Reviews, 19-Oct-2005
Acyclovir has the potential to shorten the course of illness which may result in reduced costs and morbidity associated with chickenpox.
- AD‐8 for detection of dementia across a variety of healthcare settings
Cochrane Systematic Reviews, 4-Mar-2019
Dementia assessment often involves initial screening, using a brief tool, followed by more detailed assessment where required. The AD-8 is a short questionnaire, completed by a suitable 'informant' who knows the person well. AD-8 is designed to assess cha
- Adalimumab for induction of remission in Crohn's disease
Cochrane Systematic Reviews, 14-Nov-2019
Adalimumab is an IgG1 monoclonal antibody that targets and blocks tumor necrosis factor-alpha, a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease (CD). A significant proportion of people with CD fail conventional therapy or therap
- Adalimumab for maintenance of remission in Crohn's disease
Cochrane Systematic Reviews, 16-May-2020
Conventional medications for Crohn's disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis facto
- Adalimumab for treating rheumatoid arthritis
Cochrane Systematic Reviews, 18-Sep-2008
Adalimumab is a fully human anti-TNFalpha monoclonal antibody. Published studies indicate that its use in patients with RA can be effective and safe.
- Add‐back therapy with GnRH analogues for uterine fibroids
Cochrane Systematic Reviews, 20-Mar-2015
Uterine fibroids (also known as leiomyomas) are the most common benign pelvic tumours among women. They may be asymptomatic, or may be associated with pelvic symptoms such as bleeding and pain. Medical treatment of this condition is limited and gonadotro
- Addenbrooke’s Cognitive Examination III (ACE‐III) and mini‐ACE for the detection of dementia and mild cognitive impairment
Cochrane Systematic Reviews, 17-Dec-2019
The number of new cases of dementia is projected to rise significantly over the next decade. Thus, there is a pressing need for accurate tools to detect cognitive impairment in routine clinical practice. The Addenbrooke's Cognitive Examination III (ACE-II
- Addition of anti‐leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma
Cochrane Systematic Reviews, 16-Mar-2017
Asthma management guidelines recommend low-dose inhaled corticosteroids (ICS) as first-line therapy for adults and adolescents with persistent asthma. The addition of anti-leukotriene agents to ICS offers a therapeutic option in cases of suboptimal contro
- Addition of anti‐leukotriene agents to inhaled corticosteroids for chronic asthma
Cochrane Systematic Reviews, 26-Jan-2004
Anti-leukotriene (AL) agents are being considered as 'add-on' therapy to inhaled corticosteroids (ICS), in chronic asthma.
- Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma
Cochrane Systematic Reviews, 27-Sep-2013
In the treatment of children with mild persistent asthma, low-dose inhaled corticosteroids (ICS) are recommended as the preferred monotherapy (referred to as step 2 of therapy). In children with inadequate asthma control on low doses of ICS (step 2), asth
- Addition of drug/s to a chemotherapy regimen for metastatic breast cancer
Cochrane Systematic Reviews, 10-Nov-2010
The addition of a chemotherapy drug or drugs to an established regimen is one method used to increase the dose and intensity of treatment for metastatic breast cancer.
- Addition of intravenous aminophylline to inhaled beta2‐agonists in adults with acute asthma
Cochrane Systematic Reviews, 12-Dec-2012
Asthma is a chronic condition in which sufferers may have occasional or frequent exacerbations resulting in visits to the emergency department (ED). Aminophylline has been used extensively to treat exacerbations in acute asthma settings; however, it's rol
- Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma
Cochrane Systematic Reviews, 13-Nov-2012
Inhaled beta-agonist therapy is central to the management of acute asthma. This review evaluates the benefit of an additional use of intravenous beta2-agonist agents.
- Addition of long‐acting beta2‐agonists to inhaled corticosteroids for chronic asthma in children
Cochrane Systematic Reviews, 24-Nov-2015
Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed for children with asthma.
- Addition of long‐acting beta2‐agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children
Cochrane Systematic Reviews, 12-May-2010
Long-acting inhaled ß2-adrenergic agonists (LABAs) are recommended as 'add-on' medication to inhaled corticosteroids (ICS) in the maintenance therapy of asthmatic adults and children aged two years and above.
- Addition of long‐acting beta2‐agonists to inhaled steroids as first line therapy for persistent asthma in steroid‐naive adults and children
Cochrane Systematic Reviews, 7-Oct-2009
Consensus statements recommend the addition of long-acting inhaled ß2-agonists (LABA) only in asthmatic patients who are inadequately controlled on inhaled corticosteroids (ICS). It is not uncommon for some patients to be commenced on ICS and LABA togethe
- Addition of long‐acting beta2‐agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma
Cochrane Systematic Reviews, 14-Apr-2010
In asthmatic patients inadequately controlled on inhaled corticosteroids and/or those with moderate persistent asthma, two main options are recommended: the combination of a long-acting inhaled ß2 agonist (LABA) with inhaled corticosteroids (ICS) or use o
- Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma
Cochrane Systematic Reviews, 23-Jan-2014
Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) and anti-leukotrienes (LTRA) are two treatment options that could be considered as
- Additional bedtime H2‐receptor antagonist for the control of nocturnal gastric acid breakthrough
Cochrane Systematic Reviews, 7-Oct-2009
Nocturnal gastric acid breakthrough (NAB) is defined as intragastric pH<4 for more than one continuous hour overnight. Adding H2-receptor antagonists (H2RAs) at bedtime to high-dose proton pump inhibitors is likely to enhance nocturnal gastric pH control
- Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation
Cochrane Systematic Reviews, 5-Jun-2019
Pharmacotherapies for smoking cessation increase the likelihood of achieving abstinence in a quit attempt. It is plausible that providing support, or, if support is offered, offering more intensive support or support including particular components may in
